Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Open access

Abstract

BACKGROUND: Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial stiffness, and is an important contributing factor for hypertension. Since the sodium glucose cotransport-2 (SGLT2) inhibitor empagliflozin lowers blood pressure and HbA1c in type 1 diabetes mellitus, we hypothesized that this agent would also reduce arterial stiffness and markers of sympathetic nervous system activity. METHODS: Blood pressure, arterial stiffness, heart rate variability (HRV) and circulating adrenergic mediators were measured during clamped euglycaemia (blood glucose 4-6 mmol/L) and hyperglycaemia (blood glucose 9-11 mmol/L) in 40 normotensive type 1 diabetes mellitus patients. Studies were repeated after 8 weeks of empagliflozin (25 mg once daily). RESULTS: In response to empagliflozin during clamped euglycaemia, systolic blood pressure (111 ± 9 to 109 ± 9 mmHg, p = 0.02) and augmentation indices at the radial (-52% ± 16 to -57% ± 17, p = 0.0001), carotid (+1.3 ± 1 7.0 to -5.7 ± 17.0%, p < 0.0001) and aortic positions (+0.1 ± 13.4 to -6.2 ± 14.3%, p < 0.0001) declined. Similar effects on arterial stiffness were observed during clamped hyperglycaemia without changing blood pressure under this condition. Carotid-radial pulse wave velocity decreased significantly under both glycemic conditions (p ≤ 0.0001), while declines in carotid-femoral pulse wave velocity were only significant during clamped hyperglycaemia (5.7 ± 1.1 to 5.2 ± 0.9 m/s, p = 0.0017). HRV, plasma noradrenalin and adrenaline remained unchanged under both clamped euglycemic and hyperglycemic conditions. CONCLUSIONS: Empagliflozin is associated with a decline in arterial stiffness in young type 1 diabetes mellitus subjects. The underlying mechanisms may relate to pleiotropic actions of SGLT2 inhibition, including glucose lowering, antihypertensive and weight reduction effects. CLINICAL TRIAL REGISTRATION: NCT01392560.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2840-13-28

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Physiological mechanisms implicated in arterial stiffness lowering effects with sodium glucose cotransport-2 inhibition.
Figure 1 Physiological mechanisms implicated in arterial stiffness lowering effects with sodium glucose cotransport-2 inhibition.CC BY · PubMed Central
Figure 2 The effect of empagliflozin on carotid (A) and aortic (B) augmentation indices during clamped euglycaemia and hyperglycaemia in patients with type 1 diabetes. *p < 0.0001 compared to baseline parameter under the same glycemic condition.
Figure 2 The effect of empagliflozin on carotid (A) and aortic (B) augmentation indices during clamped euglycaemia and hyperglycaemia in patients with type 1 diabetes. *p < 0.0001 compared to baseline parameter under the same glycemic condition.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. Perkins BA Cherney DZI Partridge H Soleymanlou N Tschirhart H Zinman B Fagan N Kaspers S Woerle HJ Broedl UC The sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin improves glycemic control in patients with type 1 diabetes: a single-arm clinical trial Diabetes Care 2013 in press

Cited by

See all 470

Metadata

Authors
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C.
Affiliations
  • University Health Network (CA)
  • Boehringer Ingelheim (Canada) (CA)
  • Boehringer Ingelheim (United States) (US)
  • Boehringer Ingelheim (Germany) (DE)
Corresponding author
Cherney, David ZI
Venue
Cardiovascular Diabetology
Published
2014
Volume
13
Issue
1
Pages
28
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2148513135
Cited by
470
References
63
Citations by year
2026: 11 · 2025: 19 · 2024: 27 · 2023: 30 · 2022: 40 · 2021: 52 · 2020: 55 · 2019: 46 · 2018: 49 · 2017: 46 · 2016: 49 · 2015: 33 · 2014: 12
FWCI
32.07
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Diabetology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • TSpace (University of Toronto) (submittedVersion)
Funders
  • American Society of Nephrology
  • Heart and Stroke Foundation of Canada
  • Canadian Diabetes Association
  • Kidney Foundation of Canada
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
empagliflozin, type 1 diabetes, arterial stiffness, heart rate variability, SGLT2 inhibitors, hyperglycemia, pulse wave velocity, blood pressure, sympathetic activity, norepinephrine, epinephrine, hypertension, cardiovascular complications, neurohormonal activation, augmentation index
MeSH terms
Adult, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 1, Female, Glucosides, Heart Rate, Humans, Male, Prospective Studies, Cohort Studies, Treatment Outcome, Young Adult, Vascular Stiffness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. https://app.cochat.ai/papers/10.1186/1475-2840-13-28
The paper
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014). The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-13-28

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.